Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00053144 · ClinicalTrials.gov registry record · Phase 1
Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00053144 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute.
The verdict
NCT00053144, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of combining irinotecan with cytarabine in treating patients who have refractory or recurrent acute myeloid leukemia or chronic myelogenous leukemia.
Interventions
- DRUG cytarabine
- DRUG irinotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-11 |
| Est. Completion | 2003-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00053144
The ClinicalTrials.gov registry entry for NCT00053144 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which cytarabine is the first listed.
NCT00053144 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00053144 about?
NCT00053144 is a clinical study titled "Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of combining irinotecan with cytarabine in treating patients who have r...
What is the current status of trial NCT00053144?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-11. Estimated completion is 2003-03.
What interventions are being tested in trial NCT00053144?
The interventions under investigation include: cytarabine (DRUG), irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00053144?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.